CTD Dossier Templates for the US and EU Regulatory Authorities
Accelerate Your Path to Market with Zenovel’s expert regulatory solutions from IND to MAA
Accelerate Your Path to Market with Zenovel’s expert regulatory solutions from IND to MAA
Zenovel provides Customized Common Technical Document (CTD) dossier templates for regulatory submissions to US and EU agencies, simplifying the preparation and submission of pharmaceuticals and biologics documentation, as they meet unique standards set by the EMA and the US FDA.
We offers customized CTD dossier templates for various regulatory applications, including INDs, IMPDs, MAAs, BLAs, NDAs, and ANDAs for pharmaceutical and biological goods, making them easier to understand and utilize.
Our IND templates simplify the authoring and submission of Phase I, II, and III clinical trial applications to the US FDA. These templates provide detailed information on regulatory requirements for biological and pharmaceutical goods, allowing applicants to comply with FDA expectations. The metadata also provides in-depth information on potential clinical-hold problems related to Clinical Management Control (CMC) requirements and advice on handling CMC-related clinical-hold problems.
We have developed CTD templates for US and EU biologics marketing authorization dossier submissions. These templates are encrypted with specific metadata for each agency and application, providing guidance on regulatory requirements and potential issues like application-hold and refuse-to-file. The metadata also outlines standard specifications for biological products and production processes. The applicant can adhere to unique metadata for each application type and agency, and the same CTD data package can be updated or modified for the next country-submission.
We has personalised templates simplify the creation and submission of an IMPD for clinical programmes to EU HAs and member states. These templates must satisfy pharmaceutical and biological product regulations, allowing applicants to adhere to metadata based on product type to meet HA needs and expectations.
Pharmaceutical product innovators can file for innovations in generic pharmaceuticals under the FDC Act by altering formulation, components, administration method, dosage schedule, and API using customised NDA 505(b) 2 templates. These templates provide regulatory references for most RTR concerns for all types of pharmaceutical products, including tablets, capsules, solutions, suspensions, injectable, and topical.
Insufficient understanding of GDUFA II, RTR prerequisites, and ANDA readiness can lead to ANDA rejections, costing company’s time and money. To avoid this, company should submit an ANDA using the correct data presentation strategy, including in-depth details and regulatory references for various generic medicine dosage forms.
MAA CTD templates have been prepared for EU MAAs relating to pharmaceutical items, containing encrypted metadata outlining regulatory requirements for generic pharmaceutical goods in various formulation forms such as tablets, capsules, solutions, suspensions, and injectables, to be submitted via relevant processes.
Ensure your submission meets highest standards by our deep understanding of the regulatory process- US and EU authorities.
Our pre-formatted templates and checklists are easy to edit, allowing you to customize documents.
For product registration, each template is encrypted with specific metadata prepared by regulatory experts.
Welcome to the Zenovel Blog! We are a leading provider of drug regulatory consulting and education, focusing on advancing pharmaceutical innovation while ensuring safety and compliance. This blog delves into the essentials of Drug Regulatory Affairs (DRA), covering its scope, career opportunities, and intricate processes involved in bringing new drugs
The international pharmaceutical landscape is inherently connected to the global economy and global trade, which is consisted with the quality and safety assurance , well-controlled quality and safety. Compliance with international pharmaceutical standards has changed from an optional step to a requirement. The Pharmaceutical Inspection Co-operation Scheme (PIC/S) is the
Lipinski’s Rule of 5 (Ro5) is a crucial guideline in pharmaceutical development, helping researchers evaluate a compound’s likelihood of becoming an effective oral drug. However, with the rapid evolution of therapeutic strategies, it’s worth considering the relevance of Ro5 in the current drug design landscape. Understanding Lipinski’s Rule of 5
Regulatory affairs (RA) play a crucial role in the pharmaceutical industry; ensuring products meet quality, safety, and efficacy. As the industry grow further the need for qualified professionals to bridge gaps between companies and regulators increases. This blog explores Zenovel regulatory affairs expertise, our various facets, and valuable contribution to
Navigating the world of pharmaceuticals, medical devices, and biotechnology is never straightforward. With the diversity of regulatory compliance governs the Code of Federal Regulations (CFR) – a regulatory path that shapes companies’ efforts and implements how companies long for their products to be developed, manufactured, and marketed. For companies trying
The race to deliver life-saving therapies to patients is increasingly faster and more complex. Pharmaceutical and biotech companies are faced with a dizzying list of challenges — global clinical trials, continuously changing regulations, multiple complicated therapeutic areas, and pressure to innovate. This is where Contract Research Organizations (CRO) come in:
